tetano
Editor, Senior Moderator
Mult Scler Relat Disord
. 2020 Nov;46:102592.
doi: 10.1016/j.msard.2020.102592. Epub 2020 Oct 21.
Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment
Fabio Giuseppe Masuccio[SUP] 1 [/SUP], Marianna Lo Re[SUP] 2 [/SUP], Antonio Bertolotto[SUP] 2 [/SUP], Marco Capobianco[SUP] 2 [/SUP], Claudio Solaro[SUP] 3 [/SUP]
Affiliations
Abstract
Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) represents a demyelinating disorder for which tocilizumab, an anti-IL6 receptor, has been tested to prevent disabling relapses. In a subgroup of patients affected with novel Coronavirus disease (COVID-19), tocilizumab has also increased the survival rate. We present the case of a 31-years-old Caucasian patient who experienced an almost asymptomatic Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) infection during treatment with tocilizumab, which was continued due to the very high risk of relapses of the patient. According to this case, tocilizumab might be not discontinued during COVID-19.
Keywords: Anti-IL6 receptor; COVID-19; MOGAD; Monoclonal antibody; SARS-CoV-2; Tocilizumab.
. 2020 Nov;46:102592.
doi: 10.1016/j.msard.2020.102592. Epub 2020 Oct 21.
Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment
Fabio Giuseppe Masuccio[SUP] 1 [/SUP], Marianna Lo Re[SUP] 2 [/SUP], Antonio Bertolotto[SUP] 2 [/SUP], Marco Capobianco[SUP] 2 [/SUP], Claudio Solaro[SUP] 3 [/SUP]
Affiliations
- PMID: 33296987
- DOI: 10.1016/j.msard.2020.102592
Abstract
Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) represents a demyelinating disorder for which tocilizumab, an anti-IL6 receptor, has been tested to prevent disabling relapses. In a subgroup of patients affected with novel Coronavirus disease (COVID-19), tocilizumab has also increased the survival rate. We present the case of a 31-years-old Caucasian patient who experienced an almost asymptomatic Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) infection during treatment with tocilizumab, which was continued due to the very high risk of relapses of the patient. According to this case, tocilizumab might be not discontinued during COVID-19.
Keywords: Anti-IL6 receptor; COVID-19; MOGAD; Monoclonal antibody; SARS-CoV-2; Tocilizumab.